The class action concerns whether Novo Nordisk and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. NEW YORK, Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encour ...

Core Insights - Novo Nordisk A/S (NVO) reported Q2 2025 earnings of 97 cents per ADR, surpassing the Zacks Consensus Estimate of 93 cents, and up from 65 cents per ADR in the same quarter last year [1][7] - Revenues reached $11.68 billion, a 13% increase year-over-year in Danish kroner (DKK) and an 18% increase at constant exchange rates (CER), driven by higher sales in Diabetes and Obesity Care, although total revenues fell short of the Zacks Consensus Estimate of $11.79 billion [2][7] Revenue Breakdown - The Diabetes and Obesity Care segment generated sales of DKK 71.94 billion, reflecting a 17% increase. Notably, sales of fast-acting insulin Fiasp decreased by 5%, while NovoRapid sales rose by 26% [4] - Sales of Ozempic reached DKK 31.8 billion, up 15%, while Rybelsus sales were DKK 5.65 billion, down 1%. Victoza sales saw a significant decline of 57% [5][6] - Obesity Care sales (Saxenda and Wegovy) increased by 53% to DKK 20.37 billion, with Wegovy sales growing 75% to DKK 19.53 billion, although growth was impacted by illegal compounded versions in the U.S. market [6][7] Rare Disease Segment - Sales in the Rare disease segment rose by 28% to DKK 4.92 billion, with rare blood disorder products contributing DKK 3.1 billion, up 13%. NovoSeven sales increased by 16% to DKK 2 billion [9] Cost Structure - Sales and distribution costs increased by 19% to DKK 17.53 billion, primarily due to promotional activities for Wegovy in the U.S. [10] - Research and development (R&D) costs decreased by 26% to DKK 11.69 billion, mainly due to a prior year impairment loss, despite increased investment in late-stage clinical studies [11] Outlook Revision - Novo Nordisk revised its 2025 sales growth outlook to 8-14%, down from 13-21%, and operating profit growth to 10-16%, down from 16-24%, reflecting weaker-than-expected momentum for key drugs Wegovy and Ozempic [12][13] - The company cited challenges from unregulated compounded GLP-1 alternatives and slower-than-expected uptake of Wegovy in the U.S. market [13][14] Competitive Landscape - Novo Nordisk's global diabetes market share declined by 1.4% to 32.6%, attributed to increased competition from Eli Lilly's tirzepatide products [15] - Despite the competitive pressure, Novo Nordisk aims to maintain a market share of over one-third by 2025 [15] Future Prospects - The company is optimistic about increasing Wegovy sales in the second half of 2025 through initiatives like NovoCare Pharmacy and exclusive formulary coverage with CVS [19] - Ongoing FDA reviews for expanded indications of semaglutide drugs and other pipeline candidates are expected to bolster future revenues [17][18]

（文章来源：第一财经） 在中国市场上，诺和诺德的司美格鲁肽糖尿病药物今年上半年的销售也出现11%左右的下滑。在财报公 布后的投资人电话会上，诺和诺德现任国际业务副总裁、即将于8月7日接替周赋德出任CEO的齐亚尔· 迈克·杜斯特达（Maziar Mike Doustdar）回应了投资人关于司美格鲁肽在中国市场上面临的竞争挑战。 杜斯特达表示，虽然中国GLP-1糖尿病药出现了下滑，但减重药销售是逐步增长的。他解释称，糖尿病 药销量出现下滑是由于经销商库存发生的变化；而去年刚刚获批的司美格鲁肽减重药目前还在放量阶 段，尚未进一步下沉到二、三、四线城市。 ...

Core Viewpoint - Novo Nordisk's second-quarter performance fell short of market expectations, particularly in the critical U.S. market, where the growth of its GLP-1 drug, semaglutide, has slowed down [1][2] Group 1: Financial Performance - In Q2, Novo Nordisk reported a revenue of 76.86 billion Danish Krone (approximately 11.9 billion USD), marking an 18% increase year-over-year, but below analyst expectations [1] - Semaglutide generated 7.9 billion USD in revenue, accounting for about two-thirds of total revenue, with a year-over-year sales growth of 16% [1] Group 2: Market Challenges - The slowdown in semaglutide sales in the U.S. is attributed to the entry of generic competitors, impacting Novo Nordisk's growth in this key market [2] - In China, semaglutide sales for diabetes have also seen a decline of approximately 11% in the first half of the year [2][3] Group 3: Strategic Responses - Novo Nordisk plans to implement cost-cutting measures, including the termination of eight development projects, to enhance operational efficiency [2] - The company is continuing to invest in future growth, with ongoing late-stage clinical trials for oral semaglutide and a Phase III study for Alzheimer's treatment expected to release data in Q4 [2] Group 4: Market Outlook - Despite the challenges, Novo Nordisk's new weight loss drug sales are gradually increasing, and the company remains optimistic about the Chinese market, which has a significant unmet patient demand [3] - The stock price of Novo Nordisk has dropped over 30% recently, leading to a market capitalization loss of nearly 100 billion USD, prompting analysts to lower target prices and ratings [3]

Group 1 - U.S. stock index futures are showing positive movement, with Dow futures up 0.29%, S&P 500 futures up 0.23%, and Nasdaq futures up 0.36% [1] - Chinese concept stocks are mixed in pre-market trading, with Alibaba up 1.53%, Pinduoduo up 1.07%, JD down 0.03%, Baidu up 0.87%, and Li Auto down 3.09% [2] - Uber's stock is down 0.17% in pre-market trading ahead of its Q2 earnings report scheduled for release [3] - AMD's stock is down over 5% in pre-market trading after reporting Q2 revenue that exceeded expectations but a significant drop in operating profit margin to 12% from 22% year-over-year, with adjusted net income down 31% to $781 million [4] - Advanced Micro Devices (AMD) reported a revenue increase but a decline in profitability, leading to a pre-market drop [4] Group 2 - Tesla is training a new Full Self-Driving (FSD) model, which is expected to have parameters ten times larger than the current version, with a potential public release by the end of next month [5] - Supermicro's stock is down over 16% in pre-market trading after significantly lowering its revenue guidance for the next quarter to between $6 billion and $7 billion, and reducing its fiscal 2026 revenue forecast by 17.5% to $33 billion [4] - Novo Nordisk reported a 67% year-over-year increase in sales for its weight loss drug Wegovy, reaching 19.53 billion Danish kroner in Q2 [6] - The U.S. Department of Health has withdrawn approximately $500 million in funding for mRNA vaccine development, affecting major vaccine manufacturers like Pfizer, Moderna, and Sanofi, with their stocks showing slight declines [7] - Disney has announced a significant deal involving ESPN and the NFL, exchanging equity and content rights to strengthen ties with a highly valuable sports IP, resulting in a 1.15% drop in Disney's stock [8]

Market Overview - The three major U.S. stock indices opened higher, with the Nasdaq up 0.18%, the S&P 500 up 0.14%, and the Dow Jones up 0.17% [1] Company Highlights - Apple shares rose by 1.7% after White House officials revealed that the company committed to investing an additional $100 billion in domestic manufacturing in the U.S. [1] - Nvidia's stock fell over 1% as the company issued a statement clarifying that its chips do not have backdoors, termination switches, or monitoring software [1] - Advanced Micro Devices (AMD) saw a decline of 6.6% as its adjusted net profit for the second quarter dropped 31% year-over-year, with data center business revenue growth falling short of expectations [1] - Super Micro Computer's stock plummeted by 17.6% after the company reported fourth-quarter results that missed expectations and significantly lowered its full-year revenue guidance [1] - Novo Nordisk's shares decreased by 3.2% as its second-quarter sales grew 18% year-over-year, which was below expectations, and the company anticipates a slowdown in GLP-1 drug growth in the second half of the year [1]

Core Viewpoint - Novo Nordisk's recent financial report indicates strong sales growth driven by its obesity care business, despite facing challenges in the U.S. market due to generic drug competition and slower market expansion [1][2][10]. Financial Performance - For the first half of 2025, Novo Nordisk reported sales of 154.9 billion Danish Krone (approximately 22.3 billion USD), a year-on-year increase of 18% at constant exchange rates [1]. - Operating profit reached 72.2 billion Krone (approximately 10.4 billion USD), reflecting a 29% year-on-year growth [1]. - The obesity care segment saw a remarkable sales increase of 56%, contributing significantly to overall growth [1]. Product Performance - The diabetes and obesity care division generated sales of 145.4 billion Krone (approximately 21.5 billion USD), with obesity drug sales rising 58% to 38.8 billion Krone (approximately 5.7 billion USD) [1]. - Specific product sales included Ozempic at 64.5 billion Krone (approximately 9.6 billion USD) with a 15% increase, Rybelsus at 11.3 billion Krone (approximately 1.7 billion USD) with a 5% increase, and Wegovy at 36.9 billion Krone (approximately 5.4 billion USD) with a 78% increase [1]. Market Challenges - In Q2 2025, operating profit was 33.4 billion Krone (approximately 4.8 billion USD), falling short of market expectations due to a slowdown in the U.S. market [2]. - The company has lowered its revenue and operating profit forecasts for 2025, citing decreased growth expectations for Wegovy and Ozempic in the U.S. market [10]. Industry Trends - The GLP-1 drug market is projected to exceed 17 billion USD by 2031, with a compound annual growth rate of 15.6% from 2021 to 2031 [5]. - There is a significant unmet need in obesity treatment, with only 27% of eligible patients currently receiving GLP-1 therapy in major markets [5]. Strategic Initiatives - Novo Nordisk is focusing on expanding its production capacity and adapting its product offerings to meet market demands [15][16]. - The company is investing in new facilities and partnerships to enhance its operational capabilities and direct patient outreach [11][16]. - The appointment of a new CEO aims to drive growth and navigate the competitive landscape in the metabolic disease treatment sector [14][17].

1. 8月6日(周三)美股盘前，美股三大股指期货齐涨。截至发稿，道指期货涨0.35%，标普500指数期货涨0.24%，纳指期货涨 0.23%。 2. 截至发稿，德国DAX指数涨0.02%，英国富时100指数涨0.20%，法国CAC40指数涨0.28%，欧洲斯托克50指数涨0.22%。 3. 截至发稿，WTI原油涨1.63%，报66.22美元/桶。布伦特原油涨1.52%，报68.67美元/桶。 | 瑞 伦敦布伦特原油 | 2025年10月 | 68.67 | 68.81 | 67.65 | +1.03 | +1.52% | | --- | --- | --- | --- | --- | --- | --- | | 雪 WTI原油 | 2025年9月 | 66.22 | 66.34 | 65.12 | +1.06 | +1.63% | 市场消息 降息预期凌乱，华尔街投行"吵"起来。美国"非农"数据暴雷令美联储降息预期飙升，但本周华尔街知名投行对降息分歧却在加 大。高盛、花旗均认为，9月或激进降息，摩根大通甚至认为今年可能降息125个基点。然而，美银认为今年美联储或按兵不 动，巴克莱和汇丰同样态度谨慎。未来几个月将 ...

Market Overview - US stock index futures are all up ahead of the market opening, with Dow futures rising by 0.35%, S&P 500 futures up by 0.24%, and Nasdaq futures increasing by 0.23% [1] - European indices also show positive movement, with Germany's DAX up by 0.02%, UK's FTSE 100 up by 0.20%, France's CAC40 up by 0.28%, and the Euro Stoxx 50 up by 0.22% [2][3] - WTI crude oil prices increased by 1.63% to $66.22 per barrel, while Brent crude oil rose by 1.52% to $68.67 per barrel [3][4] Economic Insights - There is a growing divergence among Wall Street investment banks regarding interest rate cuts, with Goldman Sachs and Citigroup suggesting aggressive cuts in September, while Bank of America and Barclays remain cautious [4] - The upcoming months are critical for determining the Federal Reserve's interest rate decisions, especially if employment and inflation data continue to show weakness [4] - Concerns about the credibility of government data have arisen following President Trump's criticism of employment data, which could impact the TIPS market significantly [5] Company News - Supermicro (SMCI.US) reported a 7.5% year-over-year increase in Q4 sales to $5.76 billion, but this fell short of market expectations of $6.01 billion, leading to a nearly 17% pre-market drop [7][8] - AMD (AMD.US) saw a 32% year-over-year revenue increase to $7.7 billion in Q2, but its adjusted earnings per share of $0.48 fell below expectations, resulting in a nearly 6% pre-market decline [8] - Novo Nordisk (NVO.US) reported a 32% year-over-year increase in net profit for Q2, driven by strong sales of its semaglutide products, which generated $16.68 billion in revenue [9] - Honda (HMC.US) adjusted its full-year guidance upward despite a 1.2% year-over-year decline in Q1 revenue, anticipating a reduction in tariff-related losses [10] - McDonald's (MCD.US) reported a 5.4% year-over-year revenue increase in Q2, exceeding expectations, with same-store sales growth driven primarily by higher customer spending [11] - Uber (UBER.US) exceeded revenue expectations for Q2, reporting $12.65 billion, and provided a positive outlook for Q3 [11] - Disney (DIS.US) reported Q3 earnings that surpassed expectations, although traditional TV revenue fell short, overshadowing strong performance in theme parks and streaming [12] - Lucid (LCID.US) reported a Q2 adjusted loss of $0.24 per share, below expectations, and lowered its annual production guidance to 18,000-20,000 vehicles [13] - Snap (SNAP.US) experienced a significant drop in advertising revenue growth, leading to a nearly 18% pre-market decline following its Q2 earnings report [13]

Financial Data and Key Metrics Changes - In the first six months of 2025, the company achieved 18% sales growth and 29% operating profit growth [8][42] - The gross margin decreased to 83.4% compared to 84.9% in 2024, primarily due to amortizations and depreciations related to Catalent [42] - Net profit increased by 22% and diluted earnings per share rose by 23% to DKK 12.49 [46] Business Line Data and Key Metrics Changes - U.S. Operations sales grew by 17%, while international operations grew by 19% [12] - GLP-1 diabetes care sales in the U.S. increased by 9%, driven by Ozempic, while obesity care sales surged by 58% [12][19] - Rare disease sales increased by 15%, with U.S. operations growing by 23% [15] Market Data and Key Metrics Changes - The company serves nearly 46 million patients with diabetes and obesity treatments, an increase of over 3.5 million patients compared to the first half of 2024 [10] - In international operations, GLP-1 diabetes sales increased by 10%, while obesity care sales grew by 125% [22] - The company holds a 71% market share in the GLP-1 segment in international operations [24] Company Strategy and Development Direction - The company aims to expand its diabetes and obesity markets, targeting new patient groups and physician segments [30] - A focus on innovation and operational efficiency is emphasized, with plans to enhance commercial execution [59] - The company is investing in a broad portfolio of treatments to address diverse patient segments in the obesity market [30] Management's Comments on Operating Environment and Future Outlook - Management has lowered the full-year outlook for 2025 due to lower growth expectations for Wegovy and Ozempic in the U.S. [9][49] - The company remains confident in its ability to treat more patients with chronic diseases despite the adjustments in expectations [54] - The management highlighted the importance of addressing the unmet needs in diabetes and obesity globally [28] Other Important Information - The company has initiated a Phase III clinical development program for amicretin, targeting obesity and associated comorbidities [35] - The company plans to launch oral semaglutide for obesity in the U.S. next year without supply restrictions [103] - An interim dividend of DKK 3.75 per share has been announced, reflecting a 7% increase compared to the previous year [48] Q&A Session Summary Question: What is the impact of Wegovy's formulary position with CVS? - Management is pleased with the conversion from the CVS formulary and is seeing results in line with expectations [66] Question: Has Novo initiated any litigation regarding compounding practices? - The company is prioritizing patient safety and is in dialogue with the FDA regarding illegal compounding practices, but specifics on litigation were not disclosed [68] Question: What is the outlook for growth in China? - Management clarified that the lower growth in China is due to destocking rather than loss of market share, and they are confident in future growth potential [75] Question: What changes in R&D focus can be expected? - The company will focus more on diabetes and obesity, reallocating resources to enhance growth in these core areas [82] Question: How is the company positioned for the launch of oral semaglutide? - The company is well-positioned for the launch of oral semaglutide for obesity next year, with no supply restrictions anticipated [103] Question: What are the pricing strategies for Wegovy and Ozempic? - Management is focused on volume growth but is also considering pricing strategies for the second half of the year [116]